News Image

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Provided By GlobeNewswire

Last update: Jun 4, 2025

Southlake, TX, June 04, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”) powered medical technology company focused on advancing the capabilities of ECGs/EKGs for the earlier detection of heart disease, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Device designation for its Aortic Stenosis (“AS”) ECG algorithm.

Read more at globenewswire.com

HEARTSCIENCES INC

NASDAQ:HSCS (6/12/2025, 6:19:34 PM)

After market: 3.6 0 (0%)

3.6

-0.11 (-2.96%)


HEART TEST LABORATORIES-CW27

NASDAQ:HSCSW (6/12/2025, 4:00:00 PM)

0.0523

+0 (+0.38%)



Find more stocks in the Stock Screener

Follow ChartMill for more